RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This study investigated whether inhibiting late Na(+) current by using ranolazine improved diastolic function in patients with heart failure with preserved ejection fraction (HFpEF).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JACC Heart Fail

Title: JACC. Heart failure

ISSN (Electronic): 2213-1787

ISSN (Print): 2213-1779

Publication date (Electronic): Apr 2013

Volume: 1

Issue: 2

Affiliations

[1 ] Department of Cardiology and Pneumology, Georg-August-University, Göttingen, Germany. Electronic address: lmaier@med.uni-goettingen.de.

[2 ] Gilead Sciences, Inc., Foster City, California.

[3 ] Department of Cardiology and Pneumology, Georg-August-University, Göttingen, Germany.

Article

Publisher Item ID: S2213-1779(13)00038-3

DOI: 10.1016/j.jchf.2012.12.002

PubMed ID: 24621836

SO-VID: 9250bb08-1849-4439-959b-f10b30d70e09

History

Keywords: diastolic dysfunction,heart failure with preserved ejection fraction,late I(Na) inhibition

Data availability:

Keywords: diastolic dysfunction, heart failure with preserved ejection fraction, late I(Na) inhibition

RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.

Read this article at

Abstract

Related collections

NTT Journal for Theology and the Study of Religion

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 46